CD7 CART

BIOLOGICAL2 trials

Sponsors

Hebei Senlang Biotechnology Inc., Ltd., Qi deng

Conditions

CD7+ Acute LeukemiaCD7+ LymphomaLeukemia, T Cell

Unknown Phase

Cell Therapy for CD7 Positive Acute Myeloid Leukemia or Mixed Lineage Leukemia

CompletedNCT04938115

Hebei Senlang Biotechnology Inc., Ltd.Leukemia, T Cell

Start: 2021-05-10End: 2023-10-30Updated: 2024-06-14

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

Not yet recruitingNCT07008872

Qi dengCD7+ Acute Leukemia, CD7+ Lymphoma

Start: 2025-06-01End: 2027-05-31Target: 40Updated: 2025-06-06

Related Papers

CD7 CAR-T cell therapy based on “Natural Selection” for the treatment of Relapsed or Refractory CD7-positive Hematologic Malignancies: A large cohort study

Blood2025-11-03

Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia

Blood2024-11-1923 citations

Naturally Selected CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Acute Myeloid Leukemia: Phase I Clinical Trial

Blood2023-11-029 citations

P1389: A NOVEL AND SUCCESSFUL CD7-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR REFRACTORY/RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA (MPAL)

HemaSphere2023-08-012 citations

S110: A NOVEL AND SUCCESSFUL CD7 GENE KNOCKOUT CAR-T CELL THERAPY FOR RELAPSED OR REFRACTORY T-CELL HEMATOLOGIC MALIGNANCIES

HemaSphere2022-06-012 citations

First-in-Human Clinical Study of a Novel CD7-Targeted Chimeric Antigen Receptor (CAR)-T Cell Therapy for Refractory/Relapsed Mixed Phenotype Acute Leukemia (MPAL)

Blood2021-11-054 citations

Evolution and Proliferation of CD7 CAR-T Cells Compared to CD19 CAR-T Cells Therapies for Acute Leukemia

Blood2021-11-053 citations